S 5059 · 119th Congress
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
This bill makes it easier and faster for the FDA to approve biosimilar drugs. Biosimilars are medications that are highly similar to existing biologic drugs (drugs made from living cells) but are made by different manufacturers. Right now, the approval process includes certain requirements that can slow things down.…
- Sponsor
- Moody, Ashley (R-Florida)
- Introduced
- 2026-07-21
- Policy area
- Health
- Latest action
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Digging through Congress... 🔍